缺血性心肌病心力衰竭应用曲美他嗪治疗的效果分析  

Analysis of the effect of trimetazidine in the treatment of ischemic cardiomyopathy and heart failure

作　　者：赵立平 ZHAO Li-ping(Department of Circulatory Medicine,Haicheng Central Hospital,Haicheng 114200,China)

机构地区：[1]辽宁省海城市中心医院循环内一科,114200

出　　处：《中国现代药物应用》2022年第18期113-115,共3页Chinese Journal of Modern Drug Application

摘　　要：目的 研究将曲美他嗪应用至缺血性心肌病心力衰竭治疗中的疗效。方法 82例缺血性心肌病心力衰竭患者,按照给药方式的不同分为对比组及应用组,每组41例。对比组行常规治疗,应用组行常规治疗+曲美他嗪治疗。比较两组疗效、治疗期间不良反应发生情况、治疗后6 min步行距离及治疗前后心功能指标[左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、心输出量(CO)]水平。结果 应用组治疗总有效率97.56%高于对比组的78.05%,差异具有统计学意义(P<0.05)。治疗前,两组LVESD、LVEDD、LVEF、CO比较,差异无统计学意义(P>0.05);治疗后,应用组LVESD(30.44±4.45)mm、LVEDD(45.33±3.01)mm小于对比组的(35.22±3.23)、(50.22±3.33)mm,LVEF(51.71±3.89)%、CO(4.87±1.10)L/min高于对比组的(41.78±4.23)%、(3.30±0.98)L/min,差异具有统计学意义(P<0.05)。应用组患者治疗后6 min步行距离为(423.32±25.21)m,长于对比组的(289.25±24.12)m,差异具有统计学意义(t=24.605, P<0.05)。应用组患者不良反应发生率4.88%低于对比组的24.39%,差异具有统计学意义(P<0.05)。结论 缺血性心肌病心力衰竭患者采用曲美他嗪治疗能够改善心功能,且疗效显著、安全性高,故值得临床大力推广和借鉴。Objective To study the efficacy of trimetazidine in the treatment of ischemic cardiomyopathy and heart failure.Methods A total of 82 patients with ischemic cardiomyopathy and heart failure were divided into control group and application group according to different administration methods,with 41 cases in each group.The control group was treated with conventional treatment,and the application group was treated with trimetazidine on the basis of conventional treatment.Both groups were compared in terms of clinical efficacy,occurrence of adverse reactions during treatment,6-min walking distance after treatment,and cardiac function indexes[left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),cardiac output(CO)]before and after treatment.Results The total effective rate 97.56%of the application group was higher than 78.05%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in LVESD,LVEDD,LVEF and CO between the two groups(P>0.05).After treatment,the LVESD(30.44±4.45)mm,LVEDD(45.33±3.01)mm in the application group were smaller than(35.22±3.23),(50.22±3.33)mm in the control group;the LVEF(51.71±3.89)%and CO(4.87±1.10)L/min in the application group were higher than(41.78±4.23)%and(3.30±0.98)L/min in the control group;and the differences were statistically significant(P<0.05).After treatment,the 6-min walking distance in the application group was(423.32±25.21)m,which was longer than(289.25±24.12)m in the control group,and the difference was statistically significant(t=24.605,P<0.05).The incidence of adverse reactions 4.88%in the application group was lower than 24.39%in the control group,and the difference was statistically significant(P<0.05).Conclusion Trimetazidine in the treatment of patients with ischemic cardiomyopathy and heart failure can improve cardiac function,with significant efficacy and high safety,so it is worthy of vigorous c

关 键 词：缺血性心肌病 心力衰竭 曲美他嗪 心功能 疗效 不良反应 

分 类 号：R541.6[医药卫生—心血管疾病] R542.2[医药卫生—内科学]